Skip to main content

Advertisement

Table 2 Late toxicity in breast cancer trials on regional radiotherapy

From: Adjuvant radiotherapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials

Trial late toxicity MA.20[16] EORTC[17] French[15]
MS-IM- IM-IM+ p MS-IM- IM-IM+ p MS+ IM-IM+ p
Lung          
Grade 2 0.2% 1.3 0.01 n.a. n.a. n.a. n.a. n.a. n.a.
Grade >2 0% 0% n.a. n.s.      
Any grade n.a n.a. n.a. n.a. 1.3% 4.3% <0.0001 n.a. n.a. n.a.
Lymphedema          
Grade 2 3.7% 6.8% 0.004 n.a. n.a. n.a. n.a. n.a. n.a.
Grade >2 0.4% 0.4% n.s. n.a. n.a. n.a. n.a. n.a. n.a.
Any grade (arm) n.a. n.a. n.a. 3.6% 3.8% n.s. n.a. n.a. n.a.
Cardiac          
Any grade n.a. n.a. n.a. 1.4% 1.6% n.s. 1.7% 2.2% n.s
Total late          
Any grade n.a. n.a. n.a. 21.8% 25.5% 0.006 n.a. n.a. n.a.
Grade >2 n.a. n.a. n.a. n.a. n.a. n.a. 2.3% 3.1% n.s.
  1. Late toxicitiy.
  2. n.a. = not available; n.s. = not significant; MS-IM-: no radiotherapy of the medial supraclavicular and internal mammary lymph nodes; MS-IM+: radiotherapy of the medial supraclavicular and internal mammary lymph nodes; MS+: radiotherapy of the medial supraclavicular lymph nodes.